Organigram Tops Curaleaf With $400M Aurora Cannabis Deal

Photo by TeeFarm via Pixabay.

On Tuesday, Nov. 3, 2026, Organigram Global and Aurora Cannabis signed an arrangement agreement that pulls Aurora out from under a hostile bid Curaleaf has been running since August.

The mismatch is hard to ignore. In October, Curaleaf described itself as a US$2.6 billion market-cap company and Organigram as roughly a US$200 million one. The smaller company won the board's backing anyway, with British American Tobacco's money behind it.

Below: the price and how shareholders get paid, where the cash comes from, why Aurora's board went this way, how Curaleaf has responded, and the approval path. The open question is whether Curaleaf escalates.

What Organigram Is Paying and How Shareholders Get Paid

Organigram's offer, valued at C$7.80 per share, is nearly double Aurora's C$4.03 closing price on Aug. 10, signaling a substantial premium to the market price.

Organigram will buy every outstanding Aurora share at C$7.80. That values Aurora at about C$561 million on a fully diluted equity basis, or roughly US$400 million. Sources land between US$400 million and US$411 million depending on the exchange rate they use.

The premiums are large. C$7.80 sits 93% above Aurora's unaffected Aug. 10 TSX close of C$4.03, the last trading day before Curaleaf's hostile bid surfaced. Against the Nov. 2 close, the premium is 32.4%.

Each Aurora shareholder can elect one of three options per share:

• C$7.80 in cash
• 5.8626 Organigram shares
• C$3.75 in cash plus 3.0431 Organigram shares

Don't count on getting your first choice. Elections are subject to proration, with caps of 205,826,172 Organigram shares and C$253,638,772 in cash. If one option is oversubscribed, holders get a blend.

The share-based math leans on a 20-day VWAP for Organigram of about C$1.33 as of Nov. 2. So any election involving shares floats with Organigram's stock price. The all-cash election stays fixed at C$7.80, which is the cleanest number in the package.

Where the Money Comes From: BAT and a Bigger Credit Line

Photo by TeeFarm via Pixabay.

The cash portion is funded partly by BAT, Organigram's strategic investor. BAT will put C$187.5 million into new Organigram stock at C$1.33 per share. The rest comes from cash on hand and a larger Organigram credit facility, and one outlet names ATB Financial as a financing provider.

BAT's role goes beyond writing a check. It controls 30% of Organigram's votes and has signed an irrevocable voting agreement in favour of the deal and against competing proposals. That is a heavy thumb on the scale.

The ownership picture after closing is where it gets interesting. Aurora holders would own about 35% of the combined company's economic equity and 42% of its voting power. The deal materials also put BAT near 42% economic ownership on an as-converted, fully diluted basis.

Read plainly, this is a tobacco-backed Canadian consolidation play. How much control BAT ends up holding is the detail to check in the proxy materials, because the percentages depend on conversion assumptions and which share counts you use.

Why Aurora's Board Chose Organigram Over Curaleaf

Curaleaf's hostile bid began in August, with offer documents dated Aug. 18 and an initial value of US$4 per share. On Oct. 6 it raised the offer to an implied US$5: US$1.00 in cash plus 0.4013 Curaleaf shares, based on Curaleaf's Oct. 2 close. Curaleaf called that an 86% premium and a 25% increase.

Aurora's board rejected both. It told shareholders not to tender, and anyone who already had can withdraw.

Organigram's price is about 21% above Curaleaf's latest bid on Nov. 2 valuations. Aurora executive chair and CEO Miguel Martin said the offer came out of a strategic review process.

The business logic is a pairing. Organigram brings a Canadian recreational business; Aurora brings an international medical business across Canada, Europe and Australia. The companies expect more than C$50 million in cost savings.

Europe is the thread running through it. The combined company would operate five EU-GMP-certified production and distribution facilities, building on Organigram's April purchase of Germany's Sanity Group.

Curaleaf's Response and the Open Question

Curaleaf did not fold its tent on Nov. 3. It said its Oct. 6 offer remains outstanding and argued it offers better value and greater closing certainty. It also criticized Aurora for giving Organigram due diligence access while denying it to Curaleaf.

The company said it is reviewing the Organigram deal and awaiting details on any break fee and on BAT's investor rights. Those two items are the mechanics that decide how costly it is to interrupt this transaction.

Curaleaf's offer was scheduled to expire Dec. 4. Whether it raises the bid is unconfirmed, and nothing in the public record answers that yet.

The size gap is the backdrop. Curaleaf described itself in October as a US$2.6 billion market-cap company and Organigram as roughly US$200 million. On paper Curaleaf can outspend anyone in this fight.

The market's read on Nov. 3 was mixed:

• Aurora rose more than 20% to its highest since December 2025, though other reports said about 18%
• Curaleaf rose about 7%
• Organigram fell about 5%

Aurora trading near the deal price rather than far above it suggests investors saw little near-term chance of a bidding war. Curaleaf's gain may reflect some hope of one.

Approvals, Timeline and What to Watch

Both boards approved the deal unanimously and received fairness opinions. It is structured as a court-approved plan of arrangement under British Columbia's Business Corporations Act.

Several votes stand between signing and closing:

1. Aurora needs at least two-thirds of votes cast at a special meeting.
2. Organigram's share issuance and the BAT private placement need a simple majority, excluding BAT's shares.
3. The Supreme Court of British Columbia must approve the arrangement.
4. One report cites German foreign investment clearance among the regulatory approvals.

Both shareholder meetings are expected in December 2026, with closing expected in January 2027. Those dates are expectations, not guarantees.

If you hold either stock, read the management information circular rather than relying on headlines, and talk to a licensed financial adviser. Election mechanics, proration and tax treatment can differ by where you live, and cross-border rules vary, so confirm what applies to you.

The structure matters more than the headline number. BAT's irrevocable vote makes this deal hard to dislodge, so Curaleaf would have to beat it on price and also persuade Aurora shareholders over the board's opposition. That is a harder task than simply writing a bigger check.

Two dates will tell the story: the Dec. 4 Curaleaf expiry and the December shareholder meetings. If no counter-bid appears, Canada gets a single large player spanning recreational and international medical cannabis, with a tobacco giant as its largest stakeholder.

Browse our seed collection.